莱达西贝普(Lerodalcibep) - 药物靶点：PCSK9_在研适应症：动脉粥样硬化，杂合子家族性高胆固醇血症，纯合子家族性高胆固醇血症_专利_临床

概要

基本信息

药物类型

融合蛋白

别名

HST101、LIB-003、LIB003

靶点

PCSK9

作用方式

抑制剂

作用机制

PCSK9抑制剂(前蛋白转化酶枯草杆菌蛋白酶Kexin-9抑制剂)

治疗领域

心血管疾病遗传病与畸形内分泌与代谢疾病+ [1]

在研适应症

动脉粥样硬化杂合子家族性高胆固醇血症纯合子家族性高胆固醇血症+ [8]

非在研适应症-

原研机构

LIB Therapeutics LLC

在研机构

LIB Therapeutics LLC海森生物医药有限公司

LIB Therapeutics

非在研机构-

权益机构

海森生物医药有限公司

LIB Therapeutics

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 454015655

来源: *****

关联

16

项与莱达西贝普相关的临床试验

NCT07102511

/ Not yet recruiting临床3期

Randomized, Placebo-Controlled, Double-Blind, Phase 3b Study to Evaluate the Efficacy and Safety of Lerodalcibep in Children and Adolescents, 6 to 17 Years of Age, With Heterozygous Familial Hypercholesterolemia on Stable Diet and Oral Lipid-Lowering Therapy

The goal of this clinical trial is to assess the LDL-Cholesterol reductions at Week 12 and Week 24 with monthly dosing of lerodalcibep (Lerochol) 300 mg administered subcutaneously by auto-injector (AI)/pre-filled pen (PFP) compared to placebo (dummy), in male and female pediatric patients 6 to 17 years of age, with inherited high cholesterol (HeFH) on a stable diet and maximally tolerated oral LDL C lowering drug therapy such as statins.
The main question[s] it aims to answer are:
How effective is Lerochol in reducing LDL cholesterol? How well is it tolerated and are there any safety concerns? Researchers will compare Lerochol to placebo (inert or dummy injection solution).
Participants will visit the clinic every month for months and be asked to fast overnight, but allowed to drink water, before clinic visits. Undergo physical exams, height and weight measurements, answer questions, have blood drawn from a vein in their arm, have blood pressure measurements, EKC heart tests, and receive monthly injections lasting about 5 seconds in their arms or abdomen with an autoinjector.

开始日期2025-09-01

申办/合作机构

LIB Therapeutics LLC

NCT06568471

/ Recruiting临床3期

A Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of HST101 in Chinese Patients with Hypercholesterolemia

This randomized study is to assess LDL-C reductions at Week 12 with monthly (Q4W [≤31 days]) dosing of HST101 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with atherosclerotic cardiovascular disease (ASCVD) or very-high/high risk for ASCVD including Heterozygous familial hypercholesterolemia (HeFH) on a stable diet and oral LDL-C lowering drug therapy, followed by 36-week open-label treatment with subsequent 4-week follow-up for total 52-week long-term safety and efficacy evaluation.

开始日期2024-11-16

申办/合作机构

海森生物医药有限公司

ChiCTR2400089193

/ Not yet recruiting临床3期IIT

A randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy and safety of HST101 in Chinese patients with hypercholesterolemia

开始日期2024-09-30

申办/合作机构

北京大学第一医院

[+2]

100 项与莱达西贝普相关的临床结果

登录后查看更多信息

100 项与莱达西贝普相关的转化医学

登录后查看更多信息

100 项与莱达西贝普相关的专利（医药）

登录后查看更多信息

5

项与莱达西贝普相关的文献（医药）

2025-12-01·Current Atherosclerosis Reports

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American Heart Association Scientific Sessions

Review

作者: Khoja, Adeel ; Inam, Maha ; Murthy, Nikitha ; Epstein, Elizabeth ; Virani, Salim S ; Vaughan, Elizabeth ; Sheikh, Sana ; Mehta, Sandeep ; Minhas, Abdul Mannan Khan ; Slipczuk, Leandro ; Junaid, Vashma ; Chai, Zohar ; Hinkamp, Colin ; Hermel, Melody

PURPOSE OF REVIEW:

Focused review highlighting ten select studies presented at the 2024 American Heart Association (AHA) Scientific Sessions.

RECENT FINDING:

Included studies assessed effects of intensive blood pressure control in patients with type 2 diabetes (BPROAD); decision support system for physicians to optimize early lipid lowering therapies after acute coronary syndrome (ZODIAC); efficacy and safety of zerlasiran, a short interfering RNA targeting lipoprotein(a) (ALPACAR); efficacy and safety of muvalaplin an oral disrupter of the assembly of lipoprotein(a) particles (KRAKEN); safety and efficacy of obicetrapib in patients with heterozygous familial hypercholesterolemia (BROOKLYN); efficacy and safety of lerodalcibep, a third generation PCSK9 inhibitor in heterozygous familial hypercholesterolemia subjects (LIBerate-HeFH_OLE); personalized app-based coaching to improve physical activity in patients with HFpEF compared to standard care (MyoMobile); semaglutide to improve cardiovascular outcomes in patients with a history of coronary artery bypass surgery and overweight or obesity (the SELECT trial); efficacy and safety of plozasiran in adults with genetically or clinically defined familial chylomicronemia syndrome at high risk of acute pancreatitis (PALISADE); and transcriptomic signatures and predictors of evolocumab added to maximum statin therapy based on intra-coronary plaque characteristics (YELLOW III). Research presented at the 2024 AHA Scientific Sessions emphasized innovative strategies in cardiovascular disease prevention and management.

2025-08-01·CURRENT OPINION IN LIPIDOLOGY

Safety and effectiveness of proprotein convertase subtilisin/kexin type 9 inhibition: an updated review

Review

作者: Pamporis, Konstantinos ; Tsiachris, Dimitrios ; Karakasis, Paschalis

Purpose of review:

To summarize the recent literature on the effectiveness and safety of proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) in reducing low-density lipoprotein cholesterol (LDL-C) and mitigating atherosclerotic cardiovascular disease (ASCVD) risk.

Recent findings:

PCSK9i demonstrated considerable benefits in patients with acute myocardial infarction (AMI). Within an intensive lipid-lowering strategy (“strike early-strike strong”), these agents were associated with improved outcomes, primarily through LDL-C reductions and atheromatous plaque regression and stabilization, particularly in multivessel disease. In heterozygous familial hypercholesterolemia, significant LDL-C reductions were noted for alirocumab (−43.3%) and lerodalcibep (−58.6%), while in homozygous hypercholesterolemia, lerodalcibep (−4.9%) and inclisiran (−1.68%) were ineffective, with evolocumab demonstrating a superior −10.3% LDL-C reduction. PCSK9i exhibit a favorable safety profile and high adherence rates; nevertheless, concerns have been raised in patients with respiratory comorbidities and during pregnancy. Additionally, challenges like high costs and complex authorization procedures limit their widespread implementation. Clinicians should also be mindful of the potential discontinuation of concurrent lipid-lowering therapies following PCSK9i initiation.

Summary:

PCSK9i remain integral in ASCVD risk reduction, given their potent LDL-C-lowering effects, all while maintaining a favorable safety profile. The greatest benefits are observed in patients with AMI, particularly in multivessel disease. Despite high adherence, broader utilization is hindered by persistent challenges, including costs and complex authorization processes.

2024-08-01·Current Atherosclerosis Reports

Highlights of Cardiovascular Disease Prevention Studies Presented at the 2024 American College of Cardiology Conference

Review

作者: Minhas, Abdul Mannan Khan ; Hermel, Melody ; Vaughan, Elizabeth M ; Dalakoti, Mayank ; Gupta, Kartik ; Khoja, Adeel ; Slipczuk, Leandro ; Sheikh, Sana ; Virani, Salim S ; Rawlley, Bharat ; Meloche, Chelsea

PURPOSE OF REVIEW:

To summarize selected late-breaking science on cardiovascular (CV) disease prevention presented at the 2024 Scientific Session of the American College of Cardiology (ACC) conference.

RECENT FINDINGS:

The LIBerate-HR trial showed the efficacy and safety of lerodalcibep, a subcutaneous injection that prevents binding of Pro-Protein Convertase Subtilisin/Kexin (PCSK) 9 to low-density lipoprotein (LDL)-receptors resulting in LDL-cholesterol (LDL-C) lowering in patients at very high risk or high risk of atherosclerotic CV disease (ASCVD). The AEGIS-II randomized patients with type 1 myocardial infarction (MI) with multivessel coronary artery disease and additional CV risk factors and found no benefit in major adverse CV events (MACE) with CSL112, an apolipoprotein A1 infusion shown to increase cholesterol efflux capacity. The Bridge-TIMI 73a trial showed a significant reduction in triglyceride (TG) levels with olezarsen, an antisense mRNA, in patients with moderate hyperTG with elevated CV risk. The BE ACTIVE trial showed significant improvement in step counts in patients given behavioral and financial incentives. The DRIVE study showed a significant increase in the prescription of either sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus (T2DM) at elevated CV or renal risk with a remote team-based, non-licensed navigator and clinical pharmacist approach. The TACTiC trial showed increased and sustained use of statin therapy by patient-driven use of a web-based portal that calculated the ASCVD risk score and gave prompts. The VICTORIAN-INITIATE trial showed efficacy and safety in early use of inclisiran in patients with ASCVD who did not reach target LDL-C < 70 mg/dL despite maximally tolerated statin therapy. The ARISE-HF trial showed no difference in change of peak oxygen consumption with the use of an oral aldose reductase inhibitor, AT-001, in patients with well-controlled T2DM and diabetic cardiomyopathy with high-risk features compared to placebo. The PREVENT trial showed a significant reduction in target vessel failure at 2 years in patients with non-flow limiting vulnerable plaques with percutaneous coronary intervention and optimal medical therapy (OMT) compared to OMT alone. The late-breaking clinical science presented at the 2024 Scientific Session of the ACC paves the way for an evidence-based alternative to statin therapy and provides data on several common clinical scenarios encountered in daily practice.

52

项与莱达西贝普相关的新闻（医药）

2025-11-04

·海森生物

构建亚太生物医药全链路‌，海森生物打造出海新标杆‌

2025年11月4日，海森生物医药有限公司（以下简称“海森生物”）宣布其亚太产品线在完成70起跨多国及地区上市许可转让（MAT）的同时，顺利搭建了“端对端”覆盖东南亚部分国家、澳大利亚、韩国和中国香港及中国台湾省的商业化网络。至此，海森生物正式搭建了可实现价值兑现的创新泛亚太商业化平台，为创新药企全链路出海树立了新标杆，有望惠及上千万的亚太慢病患者。从MAT到GTM（Go-to-Market）亚太全链路能力全景展现海森生物泛亚太战略布局于2024年6月大幅启动，率先完成多个品牌药品在亚太8个国家和地区的商业权益收购。同年启动商业化建设，亚太团队依托海外产品注册、市场开拓及现行药品生产质量管理规范（Current Good Manufacturing Practice for Drugs, cGMP）合规审计等核心能力，构建覆盖韩国、泰国、马来西亚、新加坡、中国香港及中国台湾省等市场的GTM体系。从MAT转移到搭建东南亚商业化平台并实现营收，海森生物只用了10个月就彻底打通全链路。 2025年10月，海森生物与泰国DKSH（大昌华嘉）业务沟通会精细化运营核心品牌搭建出海新标杆东南亚地区覆盖大约6亿人口，慢病管理市场潜力和未被满足的慢病管理需求巨大。海森生物精准瞄定本土化特色与高潜力产品，以具备东南亚典型特质的泰国生物医药市场为突破口，依托重要合作伙伴DKSH在海外产品注册、市场开拓、海外cGMP合规审计等领域的丰富渠道资源与专业经验，实现核心慢病品牌全面领跑：易达比®稳居泰国高血压血管紧张素Ⅱ受体阻断剂（ARB）市场第一，Madiplot®跻身泰国高血压第三代钙离子通道阻滞剂（CCB）市场第一，Oseni®登顶泰国糖尿病DPP-4复方制剂市场第一。三大核心品牌强势突围，超额兑现出海价值承诺。 2025年海森生物开拓泰国零售市场海森生物亚太团队自运营初期即确立“需求洞察导向战略”，通过深度需求挖掘与本地化资源精准配置，构建端对端的闭环体系。以泰国市场为例，亚太团队主导开展数十场以学术驱动为核心的专场卫星研讨会，联合区域重点医疗机构与KOL深度学术交流，实现产品认知度与品牌影响力的双重提升。该模式有效保障了策略与执行的高度协同，助力海外产品准入的快速推进及商业化落地，充分印证了海森生物作为出海平台的核心竞争力。立足中国，放眼全球。强有力的商业化运营能力是海森生物长期引以为傲的基因，随着业务范围的拓展还在逐步加强和裂变。作为社会健康价值的共创者，我们愿携手更多中国创新生物医药伙伴，构建“全球化运营+本地化落地”的双轨出海平台，以可复制的商业化解决方案赋能行业，共同成为引领全球健康产业变革的标杆力量。关于海森生物医药有限公司海森生物医药有限公司（简称：海森生物）是一家成立于2020年的创新型生物医药企业，业务聚焦于慢性病和急重症领域，致力于成为生物医药卓越商业平台和创新引领者。海森生物始终秉持以患者为中心的价值观，通过可持续的商业化造血能力，加速优质产品价值转化，提供创新的治疗方案，守护患者健康，共创社会健康价值。审批号：NP-HST-2025-11-40 往期精选海森生物I类创新药HST101中国3期临床试验顶线结果公布，降脂疗效显著！助力高血压管理“易”起达标——第19届东方心脏病学会议圆满落幕海森生物完成亚太11款产品MAT转移，加速构建全球化商业生态欢迎分享，喜欢也请点个“赞”和“在看”吧

并购

2025-10-03

·Pharmaceutical Technology

Amgen’s Phase III data supports FDA label expansion of Repatha

Takeda’s (Japan) Zejula (niraparib) was one of among six innovative anti-cancer medicines across 20 indications that were considered in this study. Credit: Melnikov Dmitriy / Shutterstock. Amgen is hopeful that Phase III data will cement the validity of its recently approved widened label for cholesterol-lowering drug Repatha (evolocumab). In August 2025, the US Food and Drug Administration (FDA) approved the use of Repatha in adults at increased risk for major adverse cardiovascular events (MACE) due to uncontrolled low-density lipoprotein cholesterol (LDL-C). Now, the VESALIUS-CV trial (NCT03872401) has proved its long-term efficacy in these patients after meeting both its primary endpoints, proving that Repatha can significantly reduce the risk of MACE in patients without a prior history of heart attack or stroke. The primary endpoints were time to first occurrence of a composite of coronary heart disease (CHD) death, heart attack or ischemic stroke, and time to first occurrence of a composite of CHD death, heart attack, ischemic stroke or any ischemia-driven arterial revascularisation. The trial enrolled more than 12,000 high-risk patients who were followed for 4.5 years. Of those enrolled, approximately 85% were maintained on a high-intensity or moderate LDL-C reducing therapy. Amgen R&D executive vice-president Dr Jay Bradner said: “The benefit across endpoints and established safety profile underscore Repatha’s role as a cornerstone therapy in comprehensive lipid management. GlobalData Strategic Intelligence US Tariffs are shifting - will you react or anticipate? Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis. By GlobalData Learn more about Strategic Intelligence “Repatha is known as a highly effective LDL-C-lowering treatment and is now the first and only PCSK9 inhibitor shown to reduce cardiovascular events in high-risk adults without prior heart attack or stroke. These additional data demonstrate that Repatha has the potential to reach tens of millions more patients earlier in their journey, before a life-altering event occurs.” Amgen has not yet released data from the trial; however, this is set to be presented at the American Heart Association Scientific Sessions on 8 November. Repatha was first approved in the US for adults with high cholesterol who require further LDL-C reduction on 27 August 2015. This came after European approval, making it the first PCSK9 inhibitor to receive regulatory clearance worldwide. Its long market presence means it is coming close to the end of its patent-protected period, due to end in 2030, opening up an opportunity for biosimilars. GlobalData predicts this will dent Amgen’s market dominance, with peak sales for the drug reaching $3.87bn in 2029 before slowly dropping, with a 2031 sales forecast of $3.32bn. GlobalData is the parent company of Clinical Trials Arena . Repatha’s main market competition comes from Praluent (alirocumab), a PCSK9 inhibitor developed by Regeneron and Sanofi, which gained US approval before Repatha, but EU approval came later. Praluent sales are set to reach $880m in 2031, according to GlobalData. After Praulent’s approval, Regeneron and Sanofi, and Amgen were embroiled in a patent dispute over the two therapies, with Amgen emerging victorious . Amgen also faces competition from Novartis’ Leqvio (inclisiran), a long-acting small-interfering RNA (siRNA) that degrades PCSK9. GlobalData predicts sales will rise sharply, from $754m in 2024 to $3.98bn in 2031. A number of LDL-C-lowering drugs have also recently shown promise, including LIB Therapeutics’ lerodalcibep, AstraZeneca’s AZD0780 and NewAmsterdam Pharma’s obicetrapib. GlobalData predicts the total dyslipidemia (high cholesterol) market will reach $15.53bn across seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan) by 2032. Pharmaceutical Technology Excellence Awards - The Benefits of Entering Gain the recognition you deserve! The Pharmaceutical Technology Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving pharmaceutical advancements. Don’t miss your chance to stand out—submit your entry today! Nominate Now

上市批准临床3期临床结果AHA会议

2025-09-05

·药通社

恒瑞年轻副总，辞职赴任CEO！

9月2日，海森生物发布消息称，刘文军担任公司首席执行官(CEO)，其将全面执掌海森生物战略规划与运营管理体系。海森生物CEO刘文军公开资料显示，刘文军乃是恒瑞前高管，其在恒瑞任职期间为公司创造了诸多亮眼的成绩，包括开拓降尿酸药非布司他院外市场、负责恒瑞用于成人2型糖尿病患者血糖控制的原研重点产品“恒格列净”的市场开发、负责恒瑞组织架构调整后的代谢疼痛产品线等。 2024年，年仅35岁的刘文军被任命为综合产品事业部副总经理，依旧主管代谢疼痛产品线，但仅任新职位一年，其于今年8月突然宣布辞职，并且去向未知。如今，刘文军的新“东家”有了着落。海森生物网站显示，集研发、生产和商业推广，覆盖全产业链的海森生物是一家创新型生物医药企业，成立于2020年，由亚洲一家专注于医疗健康行业的资产管理公司——康桥资本、合肥产投集团与合肥市肥东县共同投资组建。2023年4月，海森生物获得来自康桥资本和阿布扎比主权财富基金穆巴达拉投资公司等机构新一轮的融资，用于未来的收购和创新产品管线的业务发展。目前，公司的业务覆盖中国大陆、瑞士及泛亚太8个国家和地区，产品聚焦于慢性病和急重症治疗领域。 ↓ 扫码加入药通社交流群 ↓ 近年来，该公司为丰富其产品管线，对外收购、合作动作频频。例如，2020年12月，海森生物以3.2亿美元收购了武田制药在中国区心血管和代谢领域处方药业务，将后者包括沙坦类降压药美阿沙坦钾片(易达比)、坎地沙坦酯片(必洛斯)、伏格列波糖片(倍欣)、盐酸吡格列酮片(艾可拓)以及用于急重症的盐酸乌拉地尔注射液(亚宁定)等产品收入囊中。 2023年5月，海森生物子公司宣布与罗氏达成合作，将独家拥有注射用头孢曲松钠(罗氏芬)在中国大陆的专有权。同年9月，海森生物和LIB Therapeutics Inc.联合宣布就海森生物在大中华区(包括中国大陆和港澳台地区)开发及商业化Lerodalcibep达成许可协议。Lerodalcibep融合蛋白是由LIB Therapeutics开发的第三代长效PCSK9抑制剂，每月一针皮下注射，对解决当前临床降脂治疗中未被满足的需求具有潜力，有望助力更多高脂血症患者实现血脂控制达标，目前正处于III期临床开发阶段。 2024年6月28日，海森生物又宣布正式完成对韩国生物制药企业Celltrion旗下14种品牌产品在亚太多个国家和地区商业权益的收购，并拥有这些产品在包括韩国*、新加坡、泰国、澳大利亚、中国香港等8个国家及地区的药品上市许可持有人(MAH)权益。随着刘文军的加入，业内认为这是海森生物强化领导团队、加速业务拓展的重要信号。未来，刘文军能否助力海森生物再创佳绩，值得持续关注。 ↓⭐关注药通社，洞见行业趋势↓ 投稿/企业合作/内容沟通：药通社总编—华籍美人（Ww_150525） *添加请注明备注及来意

100 项与莱达西贝普相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
动脉粥样硬化	申请上市	美国	LIB Therapeutics LLC	2024-12-16
杂合子家族性高胆固醇血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
纯合子家族性高胆固醇血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
原发性高脂血症	申请上市	美国	LIB Therapeutics LLC	2024-12-16
原发性高胆固醇血症	临床3期	中国	海森生物医药有限公司	2024-11-16
高胆固醇血症	临床3期	法国	LIB Therapeutics LLC	2022-06-20
高胆固醇血症	临床3期	德国	LIB Therapeutics LLC	2022-06-20
高胆固醇血症	临床3期	西班牙	LIB Therapeutics LLC	2022-06-20
高胆固醇血症	临床3期	英国	LIB Therapeutics LLC	2022-06-20
高低密度脂蛋白胆固醇血症	临床3期	美国	LIB Therapeutics LLC	2021-04-22

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


CTR20242095 (NEWS) 人工标引	临床3期	高胆固醇血症	213	HST101	選夢觸憲餘壓網鹽鹹齋(鹽遞簾衊製餘蓋觸製選) = HST101 300 mg 每月一次皮下注射给药后，达到了第12周血清 LDL-C降低的主要终点衊鏇獵齋築製鹽窪獵膚 (選襯艱簾鏇觸範淵顧鑰 ) 达到更多	积极	2025-08-25
				Placebo
NCT04034485 (LIBerate-HoFH, Pubmed) 人工标引	临床3期	纯合子家族性高胆固醇血症	66	Lerodalcibep 300 mg	遞蓋襯膚憲鹹餘廠廠選(構淵餘鬱構鑰鬱鑰淵獵) = 夢鹹顧齋鹹鏇鹹簾憲築夢廠鑰鏇艱鏇壓膚網鑰 (鏇繭顧遞觸遞範壓製齋, 3.5) 更多	不佳	2025-03-01
				EvolocumabEvolocumab 420 mg	遞蓋襯膚憲鹹餘廠廠選(構淵餘鬱構鑰鬱鑰淵獵) = 鹹鑰廠鑰觸醖獵餘獵選夢廠鑰鏇艱鏇壓膚網鑰 (鏇繭顧遞觸遞範壓製齋, 3.5) 更多
NCT04798430 (LIBerate-OLE, Biospace) 人工标引	临床3期	心血管疾病 \| 纯合子家族性高胆固醇血症 \| 杂合子家族性高胆固醇血症 ... 更多	1,468	Lerodalcibep	餘淵鬱襯齋觸蓋積製餘(範觸艱鏇憲網鏇醖遞膚) = 獵齋築遞鏇襯鑰衊遞膚淵範淵淵構願築淵糧壓 (壓衊窪餘選窪獵獵構獵 ) 更多	积极	2024-12-18
NCT04806893 (Pubmed \| JAMA Cardiol) 人工标引	临床3期	心血管疾病	922	LerodalcibepLerodalcibep 300 mg	積遞鬱醖選艱選選獵願(構鏇觸範憲廠顧壓醖選) = 窪鑰夢積鬱顧夢齋醖襯顧窪鬱衊願鏇窪醖蓋蓋 (齋範蓋顧夢蓋獵夢窪窪 ) 更多	积极	2024-09-01
				Placebo	積遞鬱醖選艱選選獵願(構鏇觸範憲廠顧壓醖選) = 築窪膚蓋鹽醖壓淵顧鹹顧窪鬱衊願鏇窪醖蓋蓋 (齋範蓋顧夢蓋獵夢窪窪 )
NCT04797247 (LIBerate-CVD, BusinessWire) 人工标引	临床3期	动脉粥样硬化	922	Lerodalcibep	觸衊顧選糧夢鹽糧遞鑰(膚簾齋艱觸鏇醖鹹衊廠) = 餘壓襯構鹹願糧餘糧齋齋顧顧願淵構廠齋網窪 (遞壓遞築願膚鹹襯鏇鬱 ) 达到更多	积极	2024-05-29
				Placebo	蓋獵構鹹積選鹽淵網願(齋網鬱鏇製糧膚憲淵鏇) = 憲獵糧選獵壓鏇蓋簾膚獵淵簾獵糧製遞獵網遞 (蓋構觸獵齋範鹽壓衊襯 )
NCT05004675 (LIBerate-VI, BusinessWire) 人工标引	临床3期	动脉粥样硬化	166	Lerodalcibep 300 mg monthly	淵衊選壓憲醖廠積襯選(鹹積淵膚艱鬱壓膚選鏇) = 衊鑰鬱鏇膚餘簾鏇簾鬱淵繭顧夢構窪簾製壓鬱 (選憲醖構積齋願顧鬱範 ) 更多	积极	2024-05-29
				Inclisiran 284 mg on Day 1 and 90	淵衊選壓憲醖廠積襯選(鹹積淵膚艱鬱壓膚選鏇) = 艱蓋鏇選鹽窪簾鑰積簾淵繭顧夢構窪簾製壓鬱 (選憲醖構積齋願顧鬱範 ) 更多
NCT04806893 (LIBerate-HeFH, Biospace) 人工标引	临床3期	心血管疾病 PCSK9	922	Lerodalcibep 300 mg	顧醖艱窪膚鏇衊構築淵(鑰獵鏇憲簾壓選製網積) = 選糧艱遞遞簾獵範範醖鹹窪襯選製積艱積壓廠 (築選製淵獵廠襯壓選簾 ) 达到更多	积极	2024-04-08
NCT04798430 (LIBerate-OLE, Biospace) 人工标引	临床3期	心血管疾病	421	Lerodalcibep	淵糧繭願構淵鬱鏇鏇構(齋壓鏇憲蓋鑰鹹窪繭衊) = 網廠觸淵鑰簾淵獵鏇築簾鬱醖餘醖膚製憲艱蓋 (簾獵淵蓋蓋鑰鹽繭築衊 )	积极	2024-04-07
NCT04797104 (LIBerate-FH, Literature) 人工标引	临床3期	杂合子家族性高胆固醇血症	478	Lerodalcibep	糧積鬱網艱艱艱築簾壓(艱網獵壓餘簾鬱蓋築網) = 憲艱窪鏇範願觸繭鏇憲築鬱壓餘齋醖簾鹽積範 (鑰顧繭構觸觸觸選範鹹 ) 更多	积极	2023-08-28
				placebo	糧積鬱網艱艱艱築簾壓(艱網獵壓餘簾鬱蓋築網) = 壓淵鑰築艱繭網願願鏇築鬱壓餘齋醖簾鹽積範 (鑰顧繭構觸觸觸選範鹹 ) 更多
NCT03847974 (AHA2019) 人工标引	临床2期	高胆固醇血症	32	LIB003	鏇蓋鹽壓簾襯積壓窪選(鹽遞糧鏇鏇築簾顧艱壓) = LIB was well tolerated with all AEs considered mild and not drug related. Injection site reactions were minimal and considered mild when present. 獵觸範顧廠窪淵願憲製 (壓淵構鹽遞淵構網壓窪 ) 更多	积极	2019-11-11
				Placebo